A modified regimen of low-dose rituximab therapy for patients with refractory immune thrombocytopenia associated with systemic lupus erythematosus.

Shuo ZhangNan JiangLi WangLi ZhangHua ChenMengtao LiXiaofeng Zeng

Published in: Therapeutic advances in chronic disease (2021)

Modified low-dose RTX therapy (two infusions of 200 mg every 2 weeks) could be a promising new option for patients with SLE-associated refractory ITP with a satisfactory response rate.

Keyphrases

low dose
systemic lupus erythematosus
disease activity
high dose
diffuse large b cell lymphoma
rheumatoid arthritis
stem cells
gestational age
mesenchymal stem cells
cell therapy
smoking cessation
replacement therapy